StreetAlpha.app
Home › Stocks › ENGN

enGene Therapeutics Inc. (ENGN)

$1.74
▼ −1.14%
LAST CLOSE · NOV 20

enGene Therapeutics develops genetic medicines, led by detalimogene, a product candidate for a type of bladder cancer. It last closed at $1.74 on Nov 20, down 1.14% on the day. The next earnings report for ENGN is expected around Mon, Mar 8, 2027. For the quarter ended Jul 2026, ENGN reported EPS of -$0.47. Over its last 8 reports the stock moved an average of 9.2% the session after earnings. Over the last 12 months ENGN insiders bought $10K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ENGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ENGN.

Key Stats

Last 12 months
Results
Net income
−$130.4M
Free cash flow
−$104.0M
Valuation
Market cap
$116.6M
67.0M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.0M
At Jul 31
Debt
$25.2M
At Jul 31
Shareholder equity
$230.3M
Shares outstanding
67.0M
At Sep 2
Fiscal year endsOctober
ExchangeNasdaq
Financials history
FY2022: −$24.5M−$24.5MFY2022FY2023: −$99.9M−$99.9MFY2023FY2024: −$55.1M−$55.1MFY2024FY2025: −$117.3M−$117.3MFY2025

From ENGN's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 8). Last 12 months adds up the four latest quarters.

Next report
Mar 8
Estimated date · Time not announced
Reported EPS
-$0.47
Quarter ended Jul 2026
Year ago EPS
-$0.57
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Oct 2024: $0.34Oct '24Jan 2025: $0.48Jan '25Apr 2025: -$0.51Apr '25Jul 2025: -$0.57Jul '25Oct 2025: $3.85Oct '25Jan 2026: $0.44Jan '26Apr 2026: -$0.43Apr '26Jul 2026: -$0.47Jul '26Latest -$0.47
Revenue by quarter
Not enough quarters on file yet.
How ENGN moved after its last 8 reports
Average move the session after a report ±9.2%
Nov 12, 2026Time not announced+26.7%
Sep 8, 2026Time not announced+5.5%
Jun 15, 2026Time not announced+9.3%
Mar 9, 2026Time not announced−18.8%
Dec 22, 2025After the close+5.1%
Sep 11, 2025After the close−5.8%
Jun 12, 2025Time not announced+0.9%
Mar 10, 2025After the close−1.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ENGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ENGN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ENGN

Technical Analysis

ENGN · as of the Nov 20 close · updated each morning
Moving sideways

The stock is 0% below its 20 day and 3% below its 50 day average. It is 116% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 49). The nearest support is the swing low (Jul 29) at $1.71, and the nearest resistance the swing high (Oct 16) at $1.75.

Short trendNeutral
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 10.7%/day
Key levels
$12.2552 week high+604.0%
$3.75200 day average+115.5%
$1.81100 day average+4.0%
$1.80Pivot R1+3.4%
$1.7950 day average+2.9%
$1.75Swing high (Oct 16)+0.6%
$1.7420 day average+0.0%
$1.74Pivot+0.0%
$1.74Last close
$1.71Swing low (Jul 29)−1.7%
$1.68Pivot S1−3.4%
$1.4052 week low−19.5%
Indicators
RSI (14)48.64Middle of its rangeNeutral
MACD0.04Below its signal lineBearish
Stochastic31.4Middle of its rangeNeutral
ADX (14)22.1Weak trend
Williams %R-72.6Oversold below −80, overbought above −20Neutral
CCI (20)-0.3Oversold below −100, overbought above 100Neutral
Rate of change−0.6%Change over 10 sessionsBearish
ATR (14)$0.19Typical daily range, 10.7% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for ENGN

What happened before

See how ENGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ENGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ENGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ENGNHow many large options trades hit ENGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ENGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼28 buying vs 33 selling
  • ▼Held by funds -1.0 pts
  • ▲Funds holding +2
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5856+3.6%
In funds' top 10110.0%
Held by funds56.4%57.4%−1.0 pts
New / increased17 / 1155 / 0−49.1%
Reduced / sold out18 / 150 / 1+3200.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ENGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ENGN Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$10K1 buy · 1 insider
Sold$00 sales · 0 insiders
2026-09 bought $10KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 22William GrossmanInterim Chief Medical OfficerBuy5,102$1.97$10K
Every insider buy and sale for ENGN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ENGN insider trades →

From SEC Form 4 filings by ENGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENGN is in one of them and how their past ENGN trades turned out.

ENGN in the AI portfolios
Loading…

ENGN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ENGN in an article yet. Here's the latest on the wider market.

ENGN in the news

About enGene Therapeutics

enGene Therapeutics is a biotechnology company based in Saint-Laurent that develops genetic medicines. Its main product candidate, detalimogene, is intended for patients with a form of bladder cancer that no longer responds to BCG treatment. The company is also building a delivery platform that carries genetic medicines to mucosal tissues, with plans to apply it to other conditions such as urogenital and gastrointestinal diseases. Its products are still in preclinical and clinical development and are not yet approved for sale.

Headquarters
Saint-Laurent